Evolving Role of Biomarkers in Prostate Cancer : Episode 11
Opinion
Video
Use of Molecular Biomarkers Tests
The panel examines the significance of biomarkers in assessing therapy outcomes for prostate cancer patients, while also exploring the concept of absolute benefit in metastasis risk when adding androgen deprivation therapy (ADT) to radiation therapy for newly diagnosed cases.
Video Player is loading.
Video content above is prompted by the following question:
- What role do biomarkers play in quantifying the benefits and risks of therapy for prostate cancer patients? (Angelo A. Baccala, MD)
- Briefly discuss the use of molecular biomarkers tests, such as Prolaris, in predicting the absolute benefit in risk of metastasis of ADT added to radiation therapy in newly diagnosed prostate cancer patients.
Related Videos
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
Related Content
